A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting ...
Nov 10, 2015
0
15
Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing ...
Jul 28, 2013
0
0
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...
Jul 20, 2011
0
0
A new study involving Canada's Centre for Addiction and Mental Health (CAMH) has found a gene connected with a type of intellectual disability called Joubert syndrome.
May 12, 2011
0
0
(AP) -- Federal regulators on Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.
Jan 30, 2012
0
0
(Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. ...
Jun 4, 2013
0
0
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...
Jun 5, 2012
0
0
A breakthrough drug that could extend survival in some patients with advanced skin cancer was approved on Wednesday by US regulators, offering the first new treatment for melanoma in 13 years.
Aug 17, 2011
0
0
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.
Jul 13, 2012
0
0
deCODE Genetics, together with their colleagues from the pharmaceutical company Genentech, reported today in the journal Nature the discovery of a variant of the amyloid precursor protein (APP) gene that confers protection ...
Jul 11, 2012
0
0
Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. Trailing the founding of Cetus by five years, it was an important step in the evolution of the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
As of February 2011, Genentech employed more than 11,000 people. The Swiss pharmaceutical conglomerate Hoffmann-La Roche now completely owns Genentech after completing its purchase on March 26, 2009 for approximately $46.8 billion.
This text uses material from Wikipedia, licensed under CC BY-SA
